Combined Modality Treatment for Resectable Non-Small Cell Superior Sulcus Tumors
Lung Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring Superior Sulcus Tumor, Lung Cancer, Non-Small Cell, Multimodality Treatment, Surgery, Segmentectomy, Lobectomy, Cisplatin, CDDP, Etoposide, VP-16, VePesid, Radiation Therapy, Radiotherapy, Chest Irradiation, Prophylactic Cranial Irradiation, PCI
Eligibility Criteria
Inclusion Criteria:
- No previous treatment.
- Tumor must be resectable.
- >/= 18 and </= 70 years of age.
- Zubrod performance status </= or higher performance status if based only on pain.
- Must have adequate bone marrow, liver and renal function as defined in 3.6.
Exclusion Criteria:
- Cytological or histological proof of N3 disease.
- Evidence of metastatic disease to distant sites.
- Patients with impending cord compression will be ineligible.
Sites / Locations
- University of Texas MD Anderson Cancer Center
Arms of the Study
Arm 1
Experimental
Surgery + Radiotherapy + Chemotherapy
Surgery followed by radiotherapy and chemotherapy started at the beginning of radiotherapy. Segmentectomy or lobectomy with en bloc resection of the involved chest. Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week. Cisplatin 50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29. Etoposide given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29. Prophylactic Cranial Irradiation 25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.